BIOCARDIA BCDA 深 沪
已收盘 11-07 16:00:00 美东时间
1.30
+0.020
+1.56%
华盛通- 最 高1.32
- 今 开1.26
- 成交量 6.91万股
- 最 低 1.25
- 昨 收 1.28
- 总市值 1379.13万
- 52周最高 3.20
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.00
- 委 比 -92.19%
- 总股本 1060.87万
- 历史最高 129.00
- 量 比 0.57
- 振 幅 5.47%
- 历史最低 1.00
- 每 手 1
- 风险率 0.40%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BioCardia shares are trading higher. The company recently announced University of Wisconsin enrolled first patient in phase 3 CardiAMP HF II cell therapy pivotal trial.
BioCardia shares are trading higher. The company recently announced University ...
10-31 23:39
BioCardia Updates ATM Offering, Raising Maximum Aggregate Sale To $5,309,253
This prospectus supplement updates and amends certain information in our base prospectus, dated December 5, 2023, as supplemented by our prospectus supplement dated December 6, 2023, as further supplemented by the
10-25 04:26
BioCardia Sets Record Date for Annual Meeting
BioCardia ( ($BCDA) ) just unveiled an announcement. BioCardia, Inc. has announ...
10-08 04:52
BioCardia regains Nasdaq compliance after balance sheet improvements; shares up
BioCardia (NASDAQ:BCDA) has regained compliance with Nasdaq listing requirements. On October 1, 2025, Nasdaq confirmed BioCardia now meets the Equity Rule. Compliance follows efforts to strengthen the...
10-02 20:23
BioCardia Regains Compliance With Nasdaq Listing Requirements
BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has regained compliance with the Nasdaq Capital Market's
10-02 20:04
美股大行评级 | 潜在涨幅1650.0%！Ascendiant Capital维持GRI Bio"买入"评级，目标价上调至35美元
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从34美元升至35美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.5美元升至7.75美元
09-23 09:52
BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure
<p>BioCardia announced positive preliminary clinical consultation with Japan’s PMDA regarding the CardiAMP Heart Failure Trial results. PMDA requested additional details, including clarifications on composite endpoints, statistical power, NTproBNP subgroup rationale, patient target numbers in Japan, and clinical development status in the U.S. BioCardia is preparing responses with formal consultation expected near year-end. CEO Peter Altman expres...
09-22 12:00
BioCardia Raises $5.1 Million Through Stock Sale
BioCardia ( ($BCDA) ) has provided an update. On September 19, 2025, BioCardia,...
09-20 00:47
BioCardia Announces $6 Million Public Offering
An update from BioCardia ( ($BCDA) ) is now available. On September 18, 2025, B...
09-18 21:50
BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up
BioCardia, Inc. announced positive results from its open-label CardiAMP Cell Therapy trial for patients with chronic myocardial ischemia and refractory angina. The minimally invasive therapy showed significant improvement, with patients experiencing an average 80-second increase in exercise tolerance and an 82% reduction in angina episodes at six months. These results outperform existing FDA-approved treatments like Ranolazine and EECP. CardiAMP ...
09-18 11:00
